Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.
This agreement bolsters our mission to advance transformative therapeutics for GI disorders with significant unmet need and disease burden. The addition of fexuprazan to our pipeline, which already includes a late-stage investigational treatment for gastroparesis, further strengthens our potential to bring benefit to millions of patients with chronic and debilitating GI disorders,” said James O’Mara, Chief […]
